Siga Technologie Stock Price, News & Analysis

SIGA Technologies, Inc. (SIGA) reported second-quarter revenues of $8.7 million, driven by $7 million in international sales of oral TPOXX® to Canada. This marks a continued growth trajectory from $3 million in the previous quarter. However, net income was just $0.2 million with a diluted loss per share of $0.00. The company also announced a new share repurchase program of up to $50 million. The FDA submission for intravenous TPOXX® could expand the market, but the timeline for completion is currently uncertain due to COVID-19 impacts.

On July 29, 2021, SIGA Technologies, Inc. (SIGA) announced a webcast and conference call for August 5, 2021, at 4:30 P.M. ET, featuring CEO Dr. Phil Gomez and CFO Daniel Luckshire. The meeting aims to provide a business update. SIGA focuses on health security, primarily through its lead product, TPOXX^®, which is FDA-approved for treating smallpox. The U.S. government maintains a stockpile of 1.7 million courses of TPOXX^®. Additionally, SIGA signed a contract worth over $600 million with BARDA in September 2018 for its development.

SIGA Technologies (SIGA) has partnered with Oxford University to provide TPOXX® (tecovirimat) for treating monkeypox in the Central African Republic (CAR). This collaboration will see SIGA supplying up to 500 courses of the drug at no cost, while the Institut Pasteur of Bangui will coordinate the study. The Ministry of Health in CAR will administer TPOXX to patients affected by monkeypox. SIGA is also pursuing regulatory approval from the European Medicines Agency (EMA) to include monkeypox in the drug's label indication, anticipating approval in late 2021 or early 2022.

SIGA Technologies, Inc. (SIGA) announced the delivery of TPOXX® (tecovirimat) to Liverpool University Hospitals, UK, for compassionate treatment of a monkeypox patient. TPOXX is FDA-approved for treating smallpox and has been used in various compassionate cases, including cowpox. SIGA is expanding its regulatory approvals in the EU and Canada for broader indications to treat orthopox viruses. TPOXX is stockpiled by the U.S. Government, with an aim to provide essential health security against emerging infectious diseases.

SIGA Technologies reported approximately $3 million in international sales of oral TPOXX® for Q1 2021 and an additional $7 million in April 2021. The company noted a total revenue of $4.8 million, improving from $2.6 million in Q1 2020, highlighting a shift in sales concentration. Concurrently, SIGA repurchased 1 million shares for $6.5 million. The pandemic has not materially affected liquidity but may influence future contract awards. A conference call is scheduled for today at 4:30 PM ET to discuss these updates.

SIGA Technologies has filed a New Drug Application (NDA) with the FDA for an intravenous (IV) formulation of TPOXX to treat smallpox in adults and pediatric patients over 13 kg. This marks a significant step in expanding treatment options for patients unable to swallow oral capsules, particularly relevant amid the ongoing COVID-19 pandemic. The IV formulation leverages data from prior studies, eliminating the need for additional trials. TPOXX is the first approved smallpox antiviral, and SIGA aims to facilitate access for a broader patient population in emergencies.

SIGA Technologies, Inc. (SIGA) announced a webcast and conference call scheduled for May 6, 2021, at 4:30 P.M. ET to provide a business update. CEO Phil Gomez and CFO Daniel Luckshire will participate. SIGA specializes in health security, primarily focusing on countermeasures against biological threats. Its lead product, TPOXX®, is a treatment for smallpox, with the US holding a stockpile of 1.7 million treatment courses. The company signed a potentially $600 million contract with BARDA in 2018 for TPOXX® development and procurement.

On March 23, 2021, Cipla Therapeutics and SIGA Technologies announced a strategic partnership aimed at addressing antimicrobial resistance (AMR). With AMR identified as a top global health threat by the WHO, this collaboration seeks to leverage Cipla's antibiotic expertise and SIGA's drug development skills to deliver innovative solutions to the Biomedical Advanced Research and Development Authority (BARDA). The partnership will enhance U.S. health security by providing access to novel antibacterial drugs, notably Cipla's ZEMDRI®. The deal aligns with both companies' commitment to countering AMR and improving public health.

SIGA Technologies reported strong financial results for 2020, delivering approximately 363,000 courses of oral TPOXX® to the U.S. government, generating $113 million in revenue. In Q4 alone, revenues reached $37.8 million, compared to $26.8 million in Q4 2019. The company also secured international contracts worth up to $47 million, including a $33 million contract from Canada's Public Health Agency. Despite the challenges posed by the COVID-19 pandemic, SIGA's financial position remains stable. A conference call is scheduled for March 4, 2021, to discuss these developments.